Clinical role of the mixed cell agglutination test in the prospective management of superficial bladder tumors.
The mixed cell agglutination test allows the selection of patients with transitional cell carcinoma of the bladder who are at risk to develop invasive disease. A review of our retrospective experience and that of others reveals an overall accuracy of 78% in the prediction of tumor behavior. Current prospective studies are described and a rational, selective approach to the follow-up of bladder tumor patients, influenced by the MCA test result, is advocated.